active
ACTIVE SINCE: "2014"

Access to Roche medicines in the Ivory Coast

Since 2014, Roche and the Côte d’Ivoire Ministry of Health have worked together to improve access to cancer treatments
SGDS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
MEMBER COMPANIES:
Government 1

Since 2014, Roche and the Côte d’Ivoire Ministry of Health have worked together to improve access to cancer treatments. In 2019, a new partnership began to ensure all Ivorian patients with cancer (BC, NHL, OC, CRC, CC, Lung cancer, TNBC), hepatitis B, chronic renal anaemia and haemophilia have access to Roche medications for no (out of pocket) cost. Roche also increased investment in programs to strengthen the healthcare system, including supporting the training of Oncologists (From 4 in 2014 to 14 in 2021); enabling better access to diagnostic services and to treatment outside of the capital city; helping to reduce the patient cost burden and improving the overall patient journey.

Results and milestones

The partnership expanded access, with a 146% increase in the number of patients treated with our therapies, while reducing the cost of care per patient (~20%) and allowing control of the overall budget per spend. 3,000 patients have been treated in 2 years (all therapeutic areas combined), 1,096 in 2021 and 1,756 in 2022, including 746 women with cancer, compared to less than 100 patients in previous years.

Geographic Reach
Disease Area
  • Infectious and Parasitic Disease
  • Non-communicable diseases
See Disease Areas
Target Population
  • Women
Partner organizations
Government

Ministry of Health Ivory Coast